Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
F. Hoffmann-La Roche SARM1 compound 35
- Development stage
- Unknown
- Lead developer
- Roche
01
Overview
F. Hoffmann-La Roche SARM1 compound 35: sourced facts only. name: "We present herein the structure-guided discovery of two novel SARM1 inhibitors, 7 and 35." [PMID:40100796]; target: "We present herein the structure-guided discovery of two novel SARM1 inhibitors, 7 and 35." [PMID:40100796]; developer: "Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Grenzacherstrasse 124, 4070 Basel, Switzerland." [PMID:40100796]
02
Targets
SARM1
Beyond the preview
Go deeper on F. Hoffmann-La Roche SARM1 compound 35.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on F. Hoffmann-La Roche SARM1 compound 35.